Engineered ipilimumab variants that bind human and mouse CTLA-4.

Brett Robison¹, S J Diong¹, Anusha Kumar¹, Thomas M Moon¹, Olin Chang¹, Bryant Chau², Christine Bee³, Ishita Barman⁴, Arvind Rajpal⁵, Alan J Korman⁶, Sean West¹, Pavel Strop⁷, Peter S Lee⁸

¹Discovery Biotherapeutics, Bristol Myers Squibb, Redwood City, CA, USA.

²Large Molecule Drug Discovery, Genentech, Research and Early Development, South San Francisco, CA, USA.

³Biochemistry and Biophysics, Merck, South San Francisco, CA, USA.

⁴Protein and Antibody Portfolio, Genscript, South San Francisco, CA, USA.

⁵Research, Xaira Therapeutics, Brisbane, CA, USA.

⁶Research, Vir Biotechnology, San Francisco, CA, USA.

⁷Research, Tallac Therapeutics, Burlingame, CA, USA.

⁸Biotherapeutics and Genetic Medicine, AbbVie, South San Francisco, CA, USA.

PubMed PMC DOI PDF

Abstract

Testing of candidate monoclonal antibody therapeutics in preclinical models is an essential step in drug development. Identification of antibody therapeutic candidates that bind their human targets and cross-react to mouse orthologs is often challenging, especially for targets with low sequence homology. In such cases, surrogate antibodies that bind mouse orthologs must be used. The antibody 9D9,…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.